Basic Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2018; 24(42): 4759-4772
Published online Nov 14, 2018. doi: 10.3748/wjg.v24.i42.4759
Yiguanjian decoction enhances fetal liver stem/progenitor cell-mediated repair of liver cirrhosis through regulation of macrophage activation state
Ying Xu, Wei-Wei Fan, Wen Xu, Shi-Li Jiang, Gao-Feng Chen, Cheng Liu, Jia-Mei Chen, Hua Zhang, Ping Liu, Yong-Ping Mu
Ying Xu, Wei-Wei Fan, Wen Xu, Shi-Li Jiang, Gao-Feng Chen, Cheng Liu, Jia-Mei Chen, Hua Zhang, Ping Liu, Yong-Ping Mu, Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Ying Xu, Wei-Wei Fan, Wen Xu, Shi-Li Jiang, Gao-Feng Chen, Cheng Liu, Jia-Mei Chen, Hua Zhang, Ping Liu, Yong-Ping Mu, Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Ying Xu, Wei-Wei Fan, Wen Xu, Shi-Li Jiang, Gao-Feng Chen, Cheng Liu, Jia-Mei Chen, Hua Zhang, Ping Liu, Yong-Ping Mu, Key Laboratory of Liver and Kidney Disease of the Ministry of Education, Shanghai 201203, China
Ying Xu, Wei-Wei Fan, Wen Xu, Shi-Li Jiang, Gao-Feng Chen, Cheng Liu, Jia-Mei Chen, Hua Zhang, Ping Liu, Yong-Ping Mu, Clinical Key Laboratory of TCM of Shanghai, Shanghai 201203, China
Author contributions: Mu YP and Liu P designed the research; Xu Y, Fan WW, Xu W, and Chen JM performed the research; Zhang H contributed analytic tools; Chen GF performed pathological analysis; Mu YP, Xu Y, Jiang SL, and Liu C analyzed the data; Mu YP and Xu Y composed the paper.
Supported by the National Natural Science Foundation of China, No. 81173223, No. 81573948, and No. 81874390.
Institutional animal care and use committee statement: The experimental protocol was approved by the Animal Research Committee of Shanghai University of Traditional Chinese Medicine (No. 20130132).
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines and prepared the manuscript accordingly.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yong-Ping Mu, PhD, Associate Chief Physician, Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Pudong district, Shanghai 201203, China. ypmu8888@126.com
Telephone: +86-21-20256526 Fax: +86-21-20256521
Received: August 8, 2018
Peer-review started: August 8, 2018
First decision: October 5, 2018
Revised: October 19, 2018
Accepted: October 26, 2018
Article in press: October 26, 2018
Published online: November 14, 2018
Core Tip

Core tip: Stem cells play an important role in the treatment of end-stage liver cirrhosis, but details concerning their differentiation are still controversial. Our previous studies have indicated that Yiguanjian decoction (YGJ) has an anti-hepatic fibrosis effect. However, it remains unclear whether YGJ regulates stem cell differentiation. In this work, we found that YGJ may enhance fetal liver stem/progenitor cell-mediated repair of liver cirrhosis through regulation of macrophage activation state in cirrhosis, suggesting that YGJ in combination with stem cell transplantation may be a suitable treatment for end-stage liver cirrhosis.